Abiopharma

Xu Jiayuan 🟡 adjusted position in 214.2K shares (2 derivative) of FinVolution Group (FINV) Transaction Date: Apr 03, 2026 | Filing ID: 015435

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Disclosure of interest/ Changes in interest of Directors/ Chief Executive Officer

Mineros S.A. Appoints New Chief Financial Officer and Chief Technical Advisor

Sysco to Announce Third Quarter Fiscal Year 2026 Financial Results on April 28

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

FUSION FUEL GREEN PLC (HTOO) Files Form 6-K

NORTH AMERICAN CONSTRUCTION GROUP LTD. (NOA) Files Form 6-K

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

(50% Neutral) ARTELO BIOSCIENCES, INC. (ARTL) Announces Clinical Development Update

(10% Negative) CUE BIOPHARMA, INC. (CUE) Announces Business Combination

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

RADIOPHARM THERANOSTICS LTD (RADX) Files Form 6-K

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe